Using real-world data, researchers compared 2 chimeric antigen receptor (CAR) T-cell therapies with a bispecific antibody, ...

Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic ...

Disparities continue in younger patients, raising the need for novel interventions to mitigate challenges associated with ...

Experts at the Skin of Color Update today in New York City highlighted recent FDA-approved dermatological treatments and ...

It’s hard for practicing oncologists to stay on top of the latest clinical data, but good partnerships and clinical decision ...

Celiac disease presents a higher risk for developing malignant neoplasms, including small intestine, lymphoma, and skin ...

Combining telomere-targeting agent THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) with cemiplimab (Libtayo) demonstrated a ...

The National Comprehensive Cancer Network Policy Summit emphasized the importance of integrating diversity, equity, and ...

Trastuzumab deruxtecan (T-DXd) was effective in patients with HER2-positive (HER2+) metastatic breast cancer, with no new ...

During the first fireside chat at the Patient-Centered Oncology Care® meeting, Alyssa Schatz, MSW, of National Comprehensive ...

Here are 5 areas of specialty care that rural communities often lack, putting them at a distinct disadvantage for optimal ...

The work might take long, but cancer advocate and survivor Matthew Zachary drove home the importance of advocacy to continue ...